Cargando…
Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management
Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871575/ https://www.ncbi.nlm.nih.gov/pubmed/35200462 http://dx.doi.org/10.3390/gels8020081 |
_version_ | 1784657029177016320 |
---|---|
author | Saraogi, Gaurav Kant Tholiya, Siddharth Mishra, Yachana Mishra, Vijay Albutti, Aqel Nayak, Pallavi Tambuwala, Murtaza M. |
author_facet | Saraogi, Gaurav Kant Tholiya, Siddharth Mishra, Yachana Mishra, Vijay Albutti, Aqel Nayak, Pallavi Tambuwala, Murtaza M. |
author_sort | Saraogi, Gaurav Kant |
collection | PubMed |
description | Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to treat hyperlipidemia. This study aimed to fabricate Pravastatin-loaded nanogel for evaluation of its effect in hyperlipidemia treatment. Pravastatin-loaded chitosan nanoparticles (PS-CS-NPs) were prepared by the ionic gelation method; then, these prepared NPs were converted to nanogel by adding a specified amount of 5% poloxamer solution. Various parameters, including drug entrapment efficacy, in vitro drug release, and hemolytic activity of the developed and optimized formulation, were evaluated. The in vitro drug release of the nanogel formulation revealed the sustained release (59.63% in 24 h) of the drug. The drug excipients compatibility studies revealed no interaction between the drug and the screened excipients. Higher drug entrapment efficacy was observed. The hemolytic activity showed lesser toxicity in nanoformulation than the pure drug solution. These findings support the prospective use of orally administered pravastatin-loaded nanogel as an effective and safe nano delivery system in hyperlipidemia treatment. |
format | Online Article Text |
id | pubmed-8871575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88715752022-02-25 Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management Saraogi, Gaurav Kant Tholiya, Siddharth Mishra, Yachana Mishra, Vijay Albutti, Aqel Nayak, Pallavi Tambuwala, Murtaza M. Gels Article Hyperlipidemia is a crucial risk factor for the initiation and progression of atherosclerosis, ultimately leading to cardiovascular disease. The nanogel-based nanoplatform has emerged as an extremely promising drug delivery technology. Pravastatin Sodium (PS) is a cholesterol-lowering drug used to treat hyperlipidemia. This study aimed to fabricate Pravastatin-loaded nanogel for evaluation of its effect in hyperlipidemia treatment. Pravastatin-loaded chitosan nanoparticles (PS-CS-NPs) were prepared by the ionic gelation method; then, these prepared NPs were converted to nanogel by adding a specified amount of 5% poloxamer solution. Various parameters, including drug entrapment efficacy, in vitro drug release, and hemolytic activity of the developed and optimized formulation, were evaluated. The in vitro drug release of the nanogel formulation revealed the sustained release (59.63% in 24 h) of the drug. The drug excipients compatibility studies revealed no interaction between the drug and the screened excipients. Higher drug entrapment efficacy was observed. The hemolytic activity showed lesser toxicity in nanoformulation than the pure drug solution. These findings support the prospective use of orally administered pravastatin-loaded nanogel as an effective and safe nano delivery system in hyperlipidemia treatment. MDPI 2022-01-28 /pmc/articles/PMC8871575/ /pubmed/35200462 http://dx.doi.org/10.3390/gels8020081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saraogi, Gaurav Kant Tholiya, Siddharth Mishra, Yachana Mishra, Vijay Albutti, Aqel Nayak, Pallavi Tambuwala, Murtaza M. Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title | Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title_full | Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title_fullStr | Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title_full_unstemmed | Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title_short | Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management |
title_sort | formulation development and evaluation of pravastatin-loaded nanogel for hyperlipidemia management |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871575/ https://www.ncbi.nlm.nih.gov/pubmed/35200462 http://dx.doi.org/10.3390/gels8020081 |
work_keys_str_mv | AT saraogigauravkant formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT tholiyasiddharth formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT mishrayachana formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT mishravijay formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT albuttiaqel formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT nayakpallavi formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement AT tambuwalamurtazam formulationdevelopmentandevaluationofpravastatinloadednanogelforhyperlipidemiamanagement |